Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action.
Cynomolgus monkeys had microdialysis probes implanted under ketamine anesthesia into peripheral veins, thigh muscles, and the brain in order to sample the extracellular fluid for the concentrations of unbound nucleoside analogs. A dose of 25 mg of zidovudine or 3'-fluoro-3'-deoxythymidine (FLT) per kg was administered subcutaneously to each of three animals. Relatively high antiviral concentrations of FLT and zidovudine were present in peripheral tissues and in the brain. It was found that the concentration of zidovudine in the brain was approximately one-third of that in muscle and veins; the same relation was observed for FLT. The in vivo unbound concentrations of both drugs in the brain, muscle, and venous blood exceeded those reported to inhibit human immunodeficiency virus replication in vitro. In addition, in a correlative study we found that the appearance of p24 antigen in sera of monkeys infected with simian immunodeficiency virus was significantly delayed by both compounds (15 mg/kg three times daily for 9 days after infection). Thus, we have shown that the extracellular concentrations of unbound FLT and zidovudine in the brain and peripheral tissues attained with in vivo antiviral doses exceed in vitro antiviral concentrations.
Ljungdahl-Ståhle
E
E
Department of Virology, Karolinska Institute, Stockholm, Sweden.
Guzenda
E
E
Böttiger
D
D
Wahren
B
B
Oberg
B
B
Ståhle
L
L
D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001812:Blood-Brain Barrier / Q000502:physiology; D001921:Brain / Q000378:metabolism*; D003956:Dialysis / Q000379:methods; D015224:Dideoxynucleosides / Q000493:pharmacokinetics* / Q000494:pharmacology; D005110:Extracellular Space / Q000378:metabolism; D008252:Macaca fascicularis; D009132:Muscles / Q000378:metabolism*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D015302:Simian Immunodeficiency Virus / Q000187:drug effects / Q000502:physiology; D014018:Tissue Distribution; D014680:Veins / Q000378:metabolism*; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000493:pharmacokinetics* / Q000494:pharmacology
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D015215:Zidovudine; C002854:alovudine